Generic Name: encorafenib
Brand Name: Braftovi
Manufacturer: Pfizer Canada ULC
Therapeutic Area: Metastatic colorectal cancer
Indications: In combination with cetuximab, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by a validated test, after prior therapy.
Manufacturer Requested Reimbursement Criteria1: In combination with cetuximab, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by a validated test, after prior therapy.
Submission Type: Initial
Tumour Type: Gastrointestinal
NOC Status at Filing: Pre NOC
Project Status: Active
Companion Diagnostics: Yes
Fee Schedule1: Schedule A
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Key Milestones2 | |
|---|---|
| Call for patient/clinician input open | November 17, 2020 |
| Call for patient/clinician input closed | January 15, 2021 |
| Clarification: - Patient input submission received from Colorectal Cancer Canada and Colorectal Cancer Resource & Action Network | |
| Submission received | December 16, 2020 |
| Submission accepted | January 07, 2021 |
| Review initiated | January 08, 2021 |
| Draft CADTH review report(s) provided to sponsor for comment | March 24, 2021 |
| Deadline for sponsors comments | April 05, 2021 |
| CADTH responses on draft review report(s) provided to sponsor | May 03, 2021 |
| Expert committee meeting (initial) | May 14, 2021 |
| Draft recommendation issued to sponsor | May 27, 2021 To May 31, 2021 |
| Draft recommendation posted for stakeholder feedback | - |